DV
Dividend Vision

EDIT — Editas Medicine Inc

Editas Medicine Inc (EDIT)

Total return is -84.5% over the past 10.5 years, 465.9 points behind SPY at 381.4%. Its deepest 1-year drawdown was 59.9%.

EDIT is a single-stock equity fund that tracks Editas Medicine Inc, a biotechnology company focused on gene editing and therapeutic development. The fund does not currently distribute dividends, making it unsuitable for income-focused investors seeking regular cash distributions. This fund appeals primarily to investors interested in concentrated exposure to the biotechnology sector and companies developing gene-editing technologies, rather than those seeking dividend yield.

EDIT key facts

Asset type
Stock
Asset class
Equity
Inception date
02/03/2016
Last close
$2.82
Market cap
$457,316,288
Average volume
1473100.0
Beta
2.1
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.14